Compare ING & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ING | BSX |
|---|---|---|
| Founded | 1991 | 1979 |
| Country | Netherlands | United States |
| Employees | 64298 | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.3B | 93.4B |
| IPO Year | N/A | 2010 |
| Metric | ING | BSX |
|---|---|---|
| Price | $29.39 | $63.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 21 |
| Target Price | N/A | ★ $102.19 |
| AVG Volume (30 Days) | 3.3M | ★ 14.3M |
| Earning Date | 05-01-2026 | 04-22-2026 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | N/A | ★ 1.94 |
| Revenue | N/A | ★ $9,076,000,000.00 |
| Revenue This Year | $0.19 | $11.91 |
| Revenue Next Year | $6.78 | $10.26 |
| P/E Ratio | ★ $11.40 | $32.46 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $18.37 | $60.59 |
| 52 Week High | $31.18 | $109.50 |
| Indicator | ING | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 67.58 | 38.74 |
| Support Level | $27.96 | N/A |
| Resistance Level | $30.10 | $76.77 |
| Average True Range (ATR) | 0.54 | 1.78 |
| MACD | 0.51 | 0.24 |
| Stochastic Oscillator | 98.34 | 30.40 |
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions, ING has built up a global footprint. The 2008 financial crisis forced ING to seek government support - a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market-leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.